Exploration of Predictive factors for response to Enzaltamide in bone metastasis of Prostate cancer
Not Applicable
- Conditions
- Bone metastasis of prostate cancer
- Registration Number
- JPRN-UMIN000018634
- Lead Sponsor
- Department of Urology, Juntendo University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Male
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients treated by chemotherapy 2. Patients judged to be inappropriate to perform this study by investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method BSI responder rate 3 months, 6 months, reccurence point
- Secondary Outcome Measures
Name Time Method Response rate of 50 percent of PSA PFS, OS QOL SF-8, EPIC, FACT-P, I-PSS ,QOL score for urination OS Time to chemotherapy Expression of micro RNA in blood CTC and character change of androgen receptor